Stay updated on Pembrolizumab Post-TACE in Liver Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page
- Check6 days agoChange DetectedThe page has updated its date references, adding new dates in March 2025 while removing older dates from January and February 2025.SummaryDifference0.7%
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check42 days agoChange DetectedThe website has updated the results reporting dates for a study on pembrolizumab, including new completion and posting dates, while removing previous estimates and details about the study's status and protocol revisions.SummaryDifference7%
- Check56 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check64 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.3%
Stay in the know with updates to Pembrolizumab Post-TACE in Liver Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.